Ongoing circulation of variants such as XFG, currently tracked by the WHO as a variant under monitoring rather than a variant of concern, supports the strong trader preference for no new designation before 2027. Recent seasonal increases in cases and hospitalizations, including sharp rises in the UK where XFG accounts for over half of sequenced samples, have not triggered elevated severity or immune escape signals that would prompt reclassification. Public health agencies continue to describe overall risk as low, while updated vaccines target dominant lineages and genomic surveillance shows steady evolution within existing Omicron descendants. With limited time remaining in 2026 and no evidence of a breakthrough strain meeting VOC criteria, market pricing aligns with the pattern of gradual adaptation rather than abrupt shifts.